Danish Logistics Stock News

There wouldn't be many who think Carlsberg A/S' ( CPH:CARL B ) price-to-earnings (or "P/E") ratio of 15.4x is worth a...

Genmab (CPSE:GMAB) shares have seen a modest dip over the past week, despite strong revenue and net income growth on an annual basis. Investors are likely weighing recent price movements along with improving fundamentals for the Danish biotech company. See our latest analysis for Genmab. Genmab’s share price has dropped 3.8% over the past week but remains firmly in positive territory for the year, building on its impressive 30% 90-day share price return. While recent volatility may reflect...

Per Aarsleff Holding (CPH:PAAL B) has had a great run on the share market with its stock up by a significant 14% over...

Key Insights The projected fair value for TORM is kr.225 based on 2 Stage Free Cash Flow to Equity TORM's kr.139 share...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Embla Medical hf (CPSE:EMBLA) posted earnings forecast to grow at 14.51% per year, with revenue set to rise by 8.5% annually. Both figures are ahead of the Danish market’s expected growth. The company’s net profit margin edged up to 8.6% from 8.2% the year before. While the most recent year’s earnings growth came in at 11.7%, the broader five-year average sits at a robust 19.2% per year. Embla’s combination of faster-than-market growth and steadily improving profitability, coupled with a lack...

Recently released data indicates the Asia-Pacific mineral wool market is projected to grow at a 1.3% CAGR, reaching 15 million tons by 2035, with China accounting for nearly half of regional consumption and production, and Japan leading in market value. An especially large 37% increase in regional exports during 2024, driven primarily by China, highlights accelerating trade activity and solidifies the region’s growing importance for mineral wool producers like Rockwool. With rising...

Coloplast (CPSE:COLO B) has announced that interim CEO Lars Rasmussen will not stand for re-election to the Board at the upcoming annual general meeting in December. The search for a permanent CEO continues. See our latest analysis for Coloplast. Leadership shifts like these tend to put a spotlight on Coloplast’s next chapter, which investors are weighing against a challenging year. While recent days saw a modest 3.54% 7-day share price return, the 1-year total shareholder return has slumped...

At its Annual General Meeting held on 9 October 2025, ChemoMetec A/S approved a dividend distribution of DKK 7 per share of nominal value DKK 1. This move highlights the company's focus on returning capital to shareholders and may signal confidence in its ongoing financial stability. We'll explore how the approved dividend underscores ChemoMetec's shareholder priorities and affects its overall investment narrative. Find companies with promising cash flow potential yet trading below their...

Omeros Corporation recently announced a definitive asset purchase and license agreement granting Novo Nordisk exclusive global rights to develop and commercialize zaltenibart, an experimental antibody targeting rare blood and kidney disorders, in exchange for US$340 million upfront and potential total payments of up to US$2.1 billion plus tiered royalties. This deal marks Novo Nordisk's significant move to diversify its portfolio beyond diabetes and obesity by investing in promising...

In early October 2025, DSV A/S was named as a victim of a ransomware attack by a new hacking group called the Coinbase Cartel, which specifically targets logistics companies through data exfiltration and extortion tactics. This incident highlights the elevated and evolving cybersecurity risks facing global supply chain operators and the logistics industry as a whole. We will examine how these rising cybersecurity concerns, punctuated by the recent ransomware attack, may alter DSV's...

Recent reports have surfaced about DSV (CPSE:DSV) being targeted by a new hacking group that is focused on logistics companies. The ransomware claim highlights ongoing cybersecurity challenges for firms in the supply chain sector. See our latest analysis for DSV. DSV’s latest news comes after a challenging period for shareholders. While the company recently presented at the Xeneta Summit in Barcelona, its share price return year-to-date stands at -16.08%, and the past year’s total shareholder...

Key Insights Significant control over FLSmidth by retail investors implies that the general public has more power to...

GN Store Nord A/S ( CPH:GN ), might not be a large cap stock, but it received a lot of attention from a substantial...

If you're eyeing A.P. Møller - Mærsk and asking yourself whether now is the right time to buy, sell or just hang tight, you are certainly not alone. While many stocks have been doing a bit of a dance recently, Mærsk has shown its share of interesting moves that should catch the attention of any investor. In the short term, the share price has dipped, dropping 1.4% over the last week and 6.8% in the past month. But zoom out, and it is a very different story. The stock has climbed an impressive...

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...

The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...

Zealand Pharma's (CPH:ZEAL) stock is up by a considerable 35% over the past three months. Given the company's...

DFDS A/S' ( CPH:DFDS ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment opportunity...

Royal Unibrew (CPSE:RBREW) has kicked off a share buy-back program, beginning August 27 and running until December 19, 2025. This move typically indicates management’s confidence in the company and can influence investor attitudes. See our latest analysis for Royal Unibrew. Despite Royal Unibrew’s new buy-back program hinting at management’s confidence, the stock has lost some momentum lately. Over the past year, the total shareholder return was -7.9%, while the three-year gain was 7.7%,...

Pandora announced that CEO Alexander Lacik will retire at the next annual general meeting in March 2026, with Chief Marketing Officer Berta de Pablos-Barbier set to succeed him following her influential role in the company’s brand transformation since November 2024. This leadership transition follows a period of substantial revenue expansion and workforce growth, with de Pablos-Barbier’s deep experience across luxury and consumer goods expected to support Pandora’s continued evolution as a...

Carlsberg (CPSE:CARL B) has taken several steps to boost its presence in the UK soft drinks market, announcing a major investment in a new canning line at its Rugby facility. In addition to the expansion, the exclusive distribution of Poppi prebiotic soda adds a growth angle worth watching. See our latest analysis for Carlsberg. These strategic moves come as Carlsberg’s share price recently softened, with a 90-day return of -17.4%, even as the year-to-date share price return remains positive...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Recent market commentary has identified Coloplast as trading below its estimated fair value, highlighting anticipated earnings growth and operational progress as appealing factors for investors. This perception of undervaluation has attracted heightened attention as investors seek quality opportunities in the healthcare sector, especially during a period of optimistic European market sentiment. We'll explore how perceptions of Coloplast's undervaluation could impact its investment case and...